Truqap is a kinase inhibitor that actually works by blocking pathways that support the cancer cells survive and grow, so reduces most cancers development. Truqap is from a category of medicines named an AKT inhibitor. Truqap obtained FDA acceptance on November 17, 2023, just after beneficial benefit